Kenya vs Sudan: Average cost of drugs for extensively drug-resistant tuberculosis
Kenya
1,800 constant 2022 US$
in 2024
Sudan
1,962 constant 2022 US$
in 2023
Kenya rank
29th
Sudan rank
26th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Kenya
- Sudan
How they compare
Sudan currently reports 1,962 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya, a difference of 162 constant 2022 US$.
That makes Sudan's figure about 1.1 times Kenya's.
The two have swapped places 4 times across 6 shared years of data; in 2018 it was Sudan ahead.
Kenya ranks 29th and Sudan ranks 26th of 56 countries.
Across the 2 decades both report, Kenya averaged higher in 1 and Sudan in 1.
Head to head by decade
| Decade | Kenya | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,000 constant 2022 US$ | 5,080 constant 2022 US$ | 80 constant 2022 US$ | Sudan |
| 2020s | 2,933 constant 2022 US$ | 1,672 constant 2022 US$ | 1,262 constant 2022 US$ | Kenya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Kenya or Sudan?
- Sudan, at 1,962 constant 2022 US$ against 1,800 constant 2022 US$ in Kenya as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Kenya and Sudan?
- 162 constant 2022 US$, with Sudan ahead.
- How many years of comparable data are there for Kenya and Sudan?
- 6 years are reported by both, from 2018 to 2023.
- How do Kenya and Sudan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Kenya ranks 29th and Sudan ranks 26th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.